HomeProductsBioactive CompoundsCell CycleAurora KinaseAt-9283
Chemical structure of CAS 896466-04-9

At-9283

In Stock•Starting at $210 for 50 mg•Purity ≥ 98%
CAS No.896466-04-9
MDL No.MFCD12031513
MFC19H23N7O2
MW381.40
InChI KeyLOLPPWBBNUVNQZ-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
50 mg98%$210In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

1-Cyclopropyl-3-[3-[5-(4-morpholinylmethyl)-2-benzimidazolylidene]-1,2-dihydropyrazol-4-yl]urea is a benzimidazole derivative.

CAS No.896466-04-9
Product NameAt-9283

Biological Targets

AURKA·JAK3·FLT3·AURKB·ABL1·

Associated Conditions

multiple myeloma·non-Hodgkins lymphoma·neoplasm·leukemia
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.

International journal of cancer • Vol. 130, Issue 12 • 2012
PMID: 21796626DOI: 10.1002/ijc.26324

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.

Annals of oncology : official journal of the European Society for Medical Oncology • Vol. 23, Issue 5 • 2012
PMID: 22015452DOI: 10.1093/annonc/mdr451

Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.

Leukemia research • Vol. 35, Issue 9 • 2011
PMID: 21665275DOI: 10.1016/j.leukres.2011.05.022

Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 17, Issue 10 • 2011
PMID: 21430070PMC: PMC4163546DOI: 10.1158/1078-0432.CCR-10-3012

Documentation